Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
14-3-3ζ Constrains insulin secretion by regulating mitochondrial function in pancreatic β cells
Yves Mugabo, Cheng Zhao, Ju Jing Tan, Anindya Ghosh, Scott A. Campbell, Evgenia Fadzeyeva, Frédéric Paré, Siew Siew Pan, Maria Galipeau, Julia Ast, Johannes Broichhagen, David J. Hodson, Erin E. Mulvihill, Sophie Petropoulos, Gareth E. Lim
Yves Mugabo, Cheng Zhao, Ju Jing Tan, Anindya Ghosh, Scott A. Campbell, Evgenia Fadzeyeva, Frédéric Paré, Siew Siew Pan, Maria Galipeau, Julia Ast, Johannes Broichhagen, David J. Hodson, Erin E. Mulvihill, Sophie Petropoulos, Gareth E. Lim
View: Text | PDF
Research Article Endocrinology Metabolism

14-3-3ζ Constrains insulin secretion by regulating mitochondrial function in pancreatic β cells

  • Text
  • PDF
Abstract

While critical for neurotransmitter synthesis, 14-3-3 proteins are often assumed to have redundant functions due to their ubiquitous expression, but despite this assumption, various 14-3-3 isoforms have been implicated in regulating metabolism. We previously reported contributions of 14-3-3ζ in β cell function, but these studies were performed in tumor-derived MIN6 cells and systemic KO mice. To further characterize the regulatory roles of 14-3-3ζ in β cell function, we generated β cell–specific 14-3-3ζ–KO mice. Although no effects on β cell mass were detected, potentiated glucose-stimulated insulin secretion (GSIS), mitochondrial function, and ATP synthesis were observed. Deletion of 14-3-3ζ also altered the β cell transcriptome, as genes associated with mitochondrial respiration and oxidative phosphorylation were upregulated. Acute 14-3-3 protein inhibition in mouse and human islets recapitulated the enhancements in GSIS and mitochondrial function, suggesting that 14-3-3ζ is the critical isoform in β cells. In dysfunctional db/db islets and human islets from type 2 diabetic donors, expression of Ywhaz/YWHAZ, the gene encoding 14-3-3ζ, was inversely associated with insulin secretion, and pan–14-3-3 protein inhibition led to enhanced GSIS and mitochondrial function. Taken together, this study demonstrates important regulatory functions of 14-3-3ζ in the regulation of β cell function and provides a deeper understanding of how insulin secretion is controlled in β cells.

Authors

Yves Mugabo, Cheng Zhao, Ju Jing Tan, Anindya Ghosh, Scott A. Campbell, Evgenia Fadzeyeva, Frédéric Paré, Siew Siew Pan, Maria Galipeau, Julia Ast, Johannes Broichhagen, David J. Hodson, Erin E. Mulvihill, Sophie Petropoulos, Gareth E. Lim

×

Figure 1

14-3-3 Protein inhibition in mouse islets enhances insulin secretion, mitochondrial function, and proliferation.

Options: View larger image (or click on image) Download as PowerPoint
14-3-3 Protein inhibition in mouse islets enhances insulin secretion, mi...
(A and B) Mouse islets were incubated with 14-3-3 inhibitors (10 μM) and diazoxide (DZ, 200 μM) for 1 hour prior to 4 (4G) or 16 (16G) mM glucose for 1 hour. Insulin secretion was measured by radioimmunoassay (A) and normalized to total insulin content (B; n = mice 5–6 per group; #P < 0.05 versus DMSO 4G; *P < 0.05 and ***P < 0.001 versus DMSO 16G). (C) Combined OCR trace, with basal OCRs in the inset image, showing when islets were treated with (line A) 16 mM glucose, (line B) oligomycin (5 μM), (line C) FCCP (1 μM), and (line D) rotenone (5 μM) and antimycin (5 μM). (D and E) Glucose-induced OCR (D) and ATP-linked oxygen consumption (E) were measured (n = 5–6 mice per group; *P < 0.05 versus DMSO). (F) Biochemical ATP measurements in islets treated with 14-3-3 inhibitors (n = 4 mice per group; *P < 0.05). (G) In dispersed islets, β cell proliferation was measured by immunostaining for insulin+ and Ki-67+ β cells after 72-hour treatment with 14-3-3 inhibitors (n = 3 per group; *P < 0.05). (H) β Cell proliferation was quantified by flow cytometry–mediated detection of insulin+ and EdU+ β cells, following 72-hour treatment with 14-3-3i or harmine (10 μM each). Insulin– and EdU+ cells were also measured (n = 3 per group; *P < 0.05). (I) Cell death, defined by propidium iodide+ (PI, 0.5 μg/mL) and Hoechst 33342+ (50 ng/mL) cells, was measured in dispersed islets exposed to 14-3-3 inhibitors (10 μM each) for 72 hours (n = 3 per group; *P < 0.05). Significance was determined by 1-way ANOVA, followed by Dunnett’s test (C–E and G–I), or 2-way ANOVA, followed by Tukey’s test (A and F).

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts